Document is current
Any future updates will be listed below
-
Authors
Thrift, Aaron P.
Nguyen Wenker, Theresa H.
Godwin, Kyler
Balakrishnan, Maya
Duong, Hao T.
Loomba, Rohit
Kanwal, Fasiha
El-Serag, Hashem B. https://orcid.org/0000-0001-5964-7579
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP150587, RP200537)
National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK083266, P30 DK 56338, U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515)
Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413)
U.S. Department of Veterans Affairs (5I01CX001616-04)
National Institute on Minority Health and Health Disparities (K23MD016955)
Division of Cancer Prevention, National Cancer Institute (U01 CA230997, U01 CA230694, R01 CA186566)
National Center for Advancing Translational Sciences (5UL1TR001442)
National Heart, Lung, and Blood Institute (P01HL147835)
National Institute on Alcohol Abuse and Alcoholism (U01AA029019)
Gulf Coast Center for Precision and Environmental Health (P30ES030285)
- License Information
-
More Information
Article History
Received: 26 September 2023
Accepted: 26 March 2024
First Online: 3 May 2024
Declarations
:
: RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc. All other authors disclose no conflicts of interest.
